# A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Study · id `cardio:ct-nct01698775` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01698775](<https://clinicaltrials.gov/study/NCT01698775>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01698775

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.

## Technical summary

Registry record NCT01698775. Randomized; triple masking; primary purpose treatment. Start 2012-10-02 (actual); primary completion 2016-01-19 (actual). Results posted on 2017-02-23.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 213 participants (enrolled count; ClinicalTrials.gov record NCT01698775, source copy `cardio:ctgov-nct01698775-2018-08-09`, retrieved 2026-10-26)
- Started: 2012-10-02 (actual) (ClinicalTrials.gov record NCT01698775, source copy `cardio:ctgov-nct01698775-2018-08-09`, retrieved 2026-10-26)
- Primary completion: 2016-01-19 (actual) (ClinicalTrials.gov record NCT01698775, source copy `cardio:ctgov-nct01698775-2018-08-09`, retrieved 2026-10-26)
- Completion: 2016-01-19 (actual) (ClinicalTrials.gov record NCT01698775, source copy `cardio:ctgov-nct01698775-2018-08-09`, retrieved 2026-10-26)
- Results first posted: 2017-02-23 (ClinicalTrials.gov record NCT01698775, source copy `cardio:ctgov-nct01698775-2018-08-09`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01698775-2018-08-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Placebo to omarigliptin
- Intervention (Drug): Glipizide
- Intervention (Drug): Placebo to glipizide
- Intervention (Biological): Insulin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment (`cardio:pubmed-28449320`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d50cbeae00c3789ec328cc5690e130f84450c48ab64bfdcc326949494ef69a04
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
